CATEGORIES: CMT Type - CMT1A | Living with CMT

Young Entrepreneur with CMT1A Launches Company

by | Jan 9, 2021 | 0 comments

Dakota Reilly is a young adult based in New York who has CMT1A.

After graduating from the Fashion Institute of Technology and working in the fashion industry, Dakota realized how much she enjoys creating her own products. Since working from home is ideal for someone who has difficulty commuting, especially in New York City, Dakota decided to create her own business, Blue Bear.

Dakota launched Blue Bear in August 2020 with a full line of greeting cards, stickers and enamel pins. The products are fun and unique, with the goal of brightening your day. If you are inspired by iced coffee, plants, or a cute laptop case, you will definitely love Blue Bear. There are greeting cards for several occasions, and the stickers are weather-proof so they are great for anything you want to customize, such as a laptop, phone, or water bottle.

To check out Blue Bear’s products, please visit bluebeargifts.com. Blue Bear can also be found on Facebook and Instagram at @bluebeargifts.

Learn more on this topic

Related Blog Posts

The Long Road to Diagnosis Renews Dedication to Advocacy

The Long Road to Diagnosis Renews Dedication to Advocacy

by | Jun 1, 2015 | , , | 7 Comments

Growing up we called it “Steffi disorder.” My friends and family were as baffled as my expert neurologists. I had been diagnosed with typical Spiral Muscular Atrophy (SMA) as a toddler but never followed its progression; I never seemed to get weaker. My myriad of symptoms was distinctly different than anyone else’s I had ever met in a lifetime living in the neuromuscular community. I thought I might never find my true diagnosis, let alone others who share it with me.

Hot Off the Press – Potential Treatment for CMT1A

by | Mar 9, 2015 | , , | 53 Comments

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

by | Dec 19, 2014 | , , | 12 Comments

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

by | Aug 19, 2014 | , , | 1 Comment

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Targeting PMP22 in CMT1A Patients with Gene Duplication

by | Aug 19, 2014 | , | 1 Comment

In previous collaborative work with a group of investigators including Dr Rolf Renne from the University of Florida, Dr. Alex Murashov from East Carolina University and Dr. Lynn Hudson from the NIH-NINDS, we validated a microRNA known as miR29a as a reagent that corrected the expression level of PMP22 in rodent Schwann cells.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news